ATE330937T1 - Glyburid-zusammensetzung - Google Patents

Glyburid-zusammensetzung

Info

Publication number
ATE330937T1
ATE330937T1 AT01900328T AT01900328T ATE330937T1 AT E330937 T1 ATE330937 T1 AT E330937T1 AT 01900328 T AT01900328 T AT 01900328T AT 01900328 T AT01900328 T AT 01900328T AT E330937 T1 ATE330937 T1 AT E330937T1
Authority
AT
Austria
Prior art keywords
glyburide
composition
glyburide composition
Prior art date
Application number
AT01900328T
Other languages
English (en)
Inventor
Gillian Cave
Sarah J Nicholson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE330937T1 publication Critical patent/ATE330937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01900328T 2000-01-14 2001-01-04 Glyburid-zusammensetzung ATE330937T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14

Publications (1)

Publication Number Publication Date
ATE330937T1 true ATE330937T1 (de) 2006-07-15

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900328T ATE330937T1 (de) 2000-01-14 2001-01-04 Glyburid-zusammensetzung

Country Status (37)

Country Link
US (2) US20010036479A1 (de)
EP (1) EP1250321B1 (de)
JP (1) JP4787446B2 (de)
KR (1) KR100739906B1 (de)
CN (1) CN1210258C (de)
AR (1) AR031547A1 (de)
AT (1) ATE330937T1 (de)
AU (1) AU771705B2 (de)
BG (1) BG65782B1 (de)
BR (1) BR0107564A (de)
CA (1) CA2397294C (de)
CY (1) CY1106328T1 (de)
CZ (1) CZ20022429A3 (de)
DE (1) DE60120916T2 (de)
DK (1) DK1250321T3 (de)
EE (1) EE05020B1 (de)
ES (1) ES2264967T3 (de)
GE (1) GEP20043299B (de)
HU (1) HU228825B1 (de)
IL (2) IL150383A0 (de)
LT (1) LT5024B (de)
LV (1) LV12914B (de)
MX (1) MXPA02006835A (de)
MY (1) MY128577A (de)
NO (1) NO328152B1 (de)
NZ (1) NZ519920A (de)
PT (1) PT1250321E (de)
RO (1) RO121381B1 (de)
RU (1) RU2244707C2 (de)
SK (1) SK286925B6 (de)
TN (1) TNSN01005A1 (de)
TR (1) TR200201798T2 (de)
TW (1) TWI287989B (de)
UA (1) UA73968C2 (de)
UY (1) UY26529A1 (de)
WO (1) WO2001051463A1 (de)
ZA (1) ZA200205528B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
WO2003080056A2 (en) * 2002-03-21 2003-10-02 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
EP1741435A4 (de) * 2004-04-29 2009-11-11 Lotus Pharmaceutical Co Ltd Orale lutschtabletten mit modifizierter freisetzung und verfahren zu ihrer herstellung
RU2359677C2 (ru) * 2004-04-29 2009-06-27 Лотус Фармасьютикал Ко., Лтд Оральные таблетки с модифицированным высвобождением и способ их получения
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
KR101577554B1 (ko) 2005-08-22 2015-12-14 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
EP2026787B1 (de) * 2006-05-13 2013-12-25 Novo Nordisk A/S Repaglinid und metformin enthaltende tabletten-formulierung
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
EP1967182A1 (de) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung mit einem Rosiglitazonsalz
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8883852B2 (en) 2008-10-22 2014-11-11 University of Pittburgh—Of the Commonwealth System of Higher Education Radioprotective agents
CN102387783A (zh) 2009-02-13 2012-03-21 贝林格尔.英格海姆国际有限公司 包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物、其药物剂型、其制备方法及其在患者中改善血糖控制的用途
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP2520298A1 (de) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmazeutische Zusammensetzung enthaltend Sulfonylureas (Glibenclamid) oder Meglitinides zur Behandlung von Hyperglykämie oder zur Wachstumsförderung eines Frühgeborenen
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
MX387305B (es) 2017-04-10 2025-03-18 Melior Pharmaceuticals I Inc Tratamiento de adipocitos
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
WO2022187567A2 (en) 2021-03-04 2022-09-09 Biogen Chesapeake Llc Low-sorbing glyburide formulation and methods
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK0615445T3 (da) * 1991-12-05 1996-06-03 Alfatec Pharma Gmbh Farmaceutisk administrerbar nanosol og fremgangsmåde til fremstilling deraf
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
CN1114404C (zh) 1997-06-18 2003-07-16 史密丝克莱恩比彻姆有限公司 用噻唑烷二酮和二甲双胍治疗糖尿病
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
SK286925B6 (sk) 2009-07-06
JP2003519681A (ja) 2003-06-24
JP4787446B2 (ja) 2011-10-05
CN1210258C (zh) 2005-07-13
MY128577A (en) 2007-02-28
LV12914B (en) 2003-01-20
UA73968C2 (en) 2005-10-17
NO328152B1 (no) 2009-12-21
EP1250321A1 (de) 2002-10-23
DE60120916D1 (de) 2006-08-03
IL150383A (en) 2007-03-08
CA2397294A1 (en) 2001-07-19
US20010036479A1 (en) 2001-11-01
IL150383A0 (en) 2002-12-01
AU771705B2 (en) 2004-04-01
KR100739906B1 (ko) 2007-07-16
CZ20022429A3 (cs) 2003-06-18
TWI287989B (en) 2007-10-11
DE60120916T2 (de) 2007-02-15
AR031547A1 (es) 2003-09-24
CA2397294C (en) 2011-03-22
UY26529A1 (es) 2001-08-27
NO20023367L (no) 2002-09-04
TNSN01005A1 (en) 2005-11-10
RU2244707C2 (ru) 2005-01-20
CN1395560A (zh) 2003-02-05
EE200200393A (et) 2003-10-15
BR0107564A (pt) 2002-10-01
HUP0203852A2 (hu) 2003-04-28
CY1106328T1 (el) 2011-10-12
NO20023367D0 (no) 2002-07-12
PL356210A1 (en) 2004-06-14
RO121381B1 (ro) 2007-04-30
DK1250321T3 (da) 2006-07-31
US20030185880A1 (en) 2003-10-02
BG65782B1 (bg) 2009-11-30
KR20020073169A (ko) 2002-09-19
PT1250321E (pt) 2006-09-29
NZ519920A (en) 2004-06-25
RU2002121626A (ru) 2004-01-10
WO2001051463A1 (en) 2001-07-19
AU2474001A (en) 2001-07-24
EP1250321B1 (de) 2006-06-21
LT5024B (lt) 2003-06-25
EE05020B1 (et) 2008-06-16
US6830760B2 (en) 2004-12-14
SK9832002A3 (en) 2003-07-01
HUP0203852A3 (en) 2005-05-30
LT2002085A (en) 2003-01-27
ES2264967T3 (es) 2007-02-01
HU228825B1 (en) 2013-05-28
GEP20043299B (en) 2004-03-10
BG106870A (en) 2003-03-31
MXPA02006835A (es) 2003-01-28
ZA200205528B (en) 2003-10-10
TR200201798T2 (tr) 2002-11-21

Similar Documents

Publication Publication Date Title
DE60120916D1 (de) Glyburid-zusammensetzung
IS2932B (is) Fúlvestrant samsetning
DE60134423D1 (de) Flammhemmende polycarbonat-polyester zusammensetzung
ATE303787T1 (de) Schergelzusammensetzungen
DK1524266T3 (da) Farmaceutisk sammensætning
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
PT1315485E (pt) Composição catártica
AR028197A1 (es) Composiciones antitranspirantes
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DE60106275T8 (de) Dermatologische zusammensetzung
DE60112317D1 (de) Pestizide zusammensetzung
DE50114386D1 (de) Ng
NO20030917D0 (no) Anvendelse
DE60125415D1 (de) Formeinsatz
DE60133154D1 (de) Antistatische Zusammensetzung
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE60116858D1 (de) Zusammensetzung
DE60104016D1 (de) Pestizide zusammensetzung
ATE372338T1 (de) Deshalogenverbindungen
NO20030303D0 (no) Kalsilytiske forbindelser
NO20031837D0 (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
DE60107312D1 (de) Feste Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250321

Country of ref document: EP